Low-dose peripheral blood stem cell graft after high-dose chemotherapy - an evaluation of hematopoietic reconstitution
High-dose (HD) chemotherapy followed by autologous blood stem-cell transplantation (ASCT) is the standard treatment for multiple myeloma (MM) patients. However, the collection of sufficient peripheral blood stem cell (PBSC) grafts can be challenging, and the question arises whether reinfusion of low...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
25 April 2020
|
| In: |
BMC cancer
Year: 2020, Jahrgang: 20 |
| ISSN: | 1471-2407 |
| DOI: | 10.1186/s12885-020-06873-7 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1186/s12885-020-06873-7 |
| Verfasserangaben: | Sandra Sauer, Petra Pavel, Anita Schmitt, Martin Cremer, Mark Kriegsmann, Thomas Bruckner, Karin Jordan, Patrick Wuchter, Carsten Müller-Tidow and Katharina Kriegsmann |
| Zusammenfassung: | High-dose (HD) chemotherapy followed by autologous blood stem-cell transplantation (ASCT) is the standard treatment for multiple myeloma (MM) patients. However, the collection of sufficient peripheral blood stem cell (PBSC) grafts can be challenging, and the question arises whether reinfusion of low-dose grafts will lead to a hematopoietic recovery. |
|---|---|
| Beschreibung: | Gesehen am 28.05.2020 |
| Beschreibung: | Online Resource |
| ISSN: | 1471-2407 |
| DOI: | 10.1186/s12885-020-06873-7 |